Document is current

Article History

Received: 20 November 2024

Accepted: 17 February 2025

First Online: 11 March 2025

Declarations

:

: The cell lines, H9 (hESC) and P106 (iPSC), were supplied by WiCell on a service level agreement basis. WiCell is a non-profit organization established in 1999 to advance stem cell technologies through the supply of high-quality cell lines. The stem cell lines used in this study were derived/produced under informed consent. The H9 line (WA09) has been registered with hPSC Reg which offers the research community, legislators, regulators and the general public an in-depth overview on the current status of human pluripotent stem cell (hPSC) research. The H9 ethics statement is available at the link—. The P106 line (JHU106i) was derived under clinically compliant conditions in a study by Chou et al. (Stem Cells Translational Medicine 2015; 4:320–332, ). The Johns Hopkins University and Institute of Haematology of the Chinese Academy of Medical Sciences institutional review boards both approved the use of anonymous or deidentified human blood samples from consented adult donors and patients to generate the P106 cell line.

: N/A.

: DCH is a founder, director and shareholder in Stimuliver ApS and Stemnovate Limited. JAF serves as a consultant or advisory board member for Resolution Therapeutics, Kynos Therapeutics, Ipsen, River 2 Renal Corp., Stimuliver, Galecto Biotech, Global Clinical Trial Partners and Guidepoint and has received research grant funding from Genentech and GlaxoSmithKline.